Clinical Trial Update: A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating supplementary cholecalciferol with subcutaneous interferon beta-1a in relapsing multiple sclerosis; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Cholecalciferol (vitamin D3) supplementary treatment (cholecalciferol)
• Interferon beta-1a (subcutaneous 44 µg 3 times weekly) (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2017-12-14